"A PHASE 3 OPEN LABEL STUDY EVALUATING THE EFFICACY AND SAFETY OF PEGYLATED INTERFERON LAMBDA-1A, IN COMBINATION WITH RIBAVIRIN AND DELATASVIR, FOR TREATMENT OF CHRONIC HCV INFECTION WITH TREATMENT NAIVE GENOTYPS 1,2,3 OR 4 IN SUBJECTS CO-INFECTED WITH HIV."

Registry ID

AI452032

Source registry

HEALTH_CANADA

Status

Ongoing

Phase

PHASE3

Study type

INTERVENTIONAL

Sponsor

BRISTOL-MYERS SQUIBB CANADA

Start date

2013-08-27

Last update

2013-06-14

Conditions

• HEPATITIS C VIRUS GENOTYPE 1 OR 4
• HEPATITIS C VIRUS GENOTYPE 2 OR 3

Related clinical trials

• A PHASE 3, MULTICENTER, OPEN-LABEL STUDY TO INVESTIGATE THE EFFICACY AND SAFETY OF SOFOSBUVIR/LEDIPASVIR FIXED-DOSE COMBINATION FOR 12 WEEKS IN SUBJECTS WITH CHRONIC GENOTYPE 1 OR 4 HEPATITIS C VIRUS (HCV) AND HUMAN IMMUNODEFICIENCY VIRUS (HIV)-1 CO-INFECTION
• A PHASE 2, MULTICENTER, OPEN-LABEL STUDY TO INVESTIGATE THE SAFETY AND EFFICACY OF SOFOSBUVIR/LEDIPASVIR FIXED-DOSE COMBINATION + RIBAVIRIN ADMINISTERED IN SUBJECTS INFECTED WITH CHRONIC HCV WHO HAVE ADVANCED LIVER DISEASE OR ARE POST-LIVER TRANSPLANT

View on source registry